Biogen Inc.

NasdaqGS:BIIB Rapport sur les actions

Capitalisation boursière : US$22.7b

Biogen Bilan de santé

Santé financière contrôle des critères 6/6

Biogen possède un total de capitaux propres de $16.4B et une dette totale de $6.3B, ce qui porte son ratio d'endettement à 38.5%. Son actif total et son passif total sont $28.3B et de $12.0B. L'EBIT de Biogen est $2.3B ce qui fait que son ratio de couverture des intérêts 11.9. Elle dispose de liquidités et de placements à court terme de $1.7B.

Informations clés

38.5%

Ratio d'endettement

US$6.29b

Dette

Ratio de couverture des intérêts11.9x
Argent liquideUS$1.70b
Fonds propresUS$16.36b
Total du passifUS$11.95b
Total des actifsUS$28.31b

Mises à jour récentes de la santé financière

Recent updates

Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter

Oct 31

Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?

Oct 01
Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?

What You Can Learn From Biogen Inc.'s (NASDAQ:BIIB) P/E

Sep 04
What You Can Learn From Biogen Inc.'s (NASDAQ:BIIB) P/E

Biogen: Q2 Earnings, Share Price May Have Bottomed Out As CEO Makes Mark

Aug 17

Biogen Stock: Cheapish, But With Few Growth Prospects

Jul 11

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

May 23
Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)

Apr 29

Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Apr 28
Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

The Price Is Right For Biogen Inc. (NASDAQ:BIIB)

Apr 15
The Price Is Right For Biogen Inc. (NASDAQ:BIIB)

We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Feb 21
We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Feb 16
Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade)

Feb 14

Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly

Jan 31
Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly

Biotech And Pharma Diversification Pays Off

Jan 25

Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult

Dec 26
Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult

An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued

Oct 21
An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Oct 03
Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?

Jul 16
Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de BIIB ( $6.8B ) dépassent ses passifs à court terme ( $5.4B ).

Passif à long terme: Les actifs à court terme de BIIB ( $6.8B ) dépassent ses passifs à long terme ( $6.5B ).


Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de BIIB ( 28.1% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de BIIB a été réduit de 42.5% à 38.5% au cours des 5 dernières années.

Couverture de la dette: La dette de BIIB est bien couverte par le flux de trésorerie opérationnel ( 33.8% ).

Couverture des intérêts: Les paiements d'intérêts de BIIB sur sa dette sont bien couverts par l'EBIT ( 11.9 x couverture).


Bilan


Découvrir des entreprises saines